Need professional-grade analysis? Visit stockanalysis.com
$468.51M
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
Upstream Bio, Inc. (UPB) Price Performance
Upstream Bio, Inc. (UPB) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $8.67, up 0.06% from the previous close.
Over the past year, UPB has traded between a low of $6.07 and a high of $32.60. The stock has gained 13.6% over this period. It is currently 73.4% below its 52-week high.
Upstream Bio, Inc. has a market capitalization of $468.51M.
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Company Info
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- $2.80M
- EBITDA
- $-140,332,000
- Profit Margin
- -2650.04%
- EPS (TTM)
- -6.40
- Book Value
- 7.01
Technical Indicators
- 52 Week High
- $33.68
- 52 Week Low
- $5.14
- 50 Day MA
- $20.72
- 200 Day MA
- $19.14
- Beta
- N/A
Valuation
- Trailing P/E
- N/A
- Forward P/E
- -2.79
- Price/Sales
- 167.39
- Price/Book
- 1.24
- Enterprise Value
- $97.51M